Cooley: Amolyt Pharma Agrees to Be Acquired by AstraZeneca in Up to $1.05B Cross-Border Transaction
March 16, 2024
March 16, 2024
PALO ALTO, California, March 16 -- Cooley, a law firm, issued the following news release:
Cooley advised Amolyt Pharma, a global clinical-stage biopharmaceutical company based in Lyon, France, that specializes in developing therapeutic peptides for rare endocrine and related diseases, on its definitive agreement to be acquired by AstraZeneca for up to $1.05 billion in cash. Partners Jamie Leigh, Bill Roegge, Laura Berezin and Marc Recht led the Cooley team advising Amolyt.
Cooley advised Amolyt Pharma, a global clinical-stage biopharmaceutical company based in Lyon, France, that specializes in developing therapeutic peptides for rare endocrine and related diseases, on its definitive agreement to be acquired by AstraZeneca for up to $1.05 billion in cash. Partners Jamie Leigh, Bill Roegge, Laura Berezin and Marc Recht led the Cooley team advising Amolyt.